BOLD (Boundless Bio) Marketable Securities: $75.36 Mil (As of Mar. 2026)


BOLD Boundless Bio Inc BOLD
14 GF Score
Price $2.50
! 3 Warning Signs
View Full Analysis

What is Boundless Bio Marketable Securities?

Boundless Bio BOLD 14 Marketable Securities is $75.36 Mil as of Mar. 2026. GuruFocus rates BOLD with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Boundless Bio's Marketable Securities for the quarter that ended in Mar. 2026 was $75.36 Mil.

Boundless Bio's annual Marketable Securities increased from Dec. 2023 ($97.05 Mil) to Dec. 2024 ($125.53 Mil) but then declined from Dec. 2024 ($125.53 Mil) to Dec. 2025 ($89.71 Mil).

Boundless Bio  (NAS:BOLD) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Boundless Bio Marketable Securities Related Terms

Boundless Bio Marketable Securities Historical Data

* Premium members only.

The historical data trend for Boundless Bio's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boundless Bio Marketable Securities Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
38.74 55.77 97.05 125.53 89.71

Boundless Bio Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 123.14 112.45 102.59 89.71 75.36
BOLD
14GF Score
Boundless Bio Inc BOLD
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boundless Bio Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $75.36 Mil mean?
Boundless Bio (BOLD) has a Marketable Securities of $75.36 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Boundless Bio and its competitors.
Is Boundless Bio's Marketable Securities too high?
Boundless Bio's current Marketable Securities is $75.36 Mil. Overall, Boundless Bio has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Boundless Bio's Marketable Securities compare to INKT and FLNA?
Boundless Bio's Marketable Securities of $75.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Boundless Bio and its competitors. Boundless Bio's current Marketable Securities is $75.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boundless Bio stock overvalued right now?
Boundless Bio (BOLD) has a current Marketable Securities of $75.36 Mil. The current Marketable Securities is $75.36 Mil. Boundless Bio's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Boundless Bio (BOLD), the current Marketable Securities is $75.36 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Boundless Bio Business Description

Address 10955 Alexandria Way, Suite 100, San Diego, CA, USA, 92121
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
14GF Score

Get the complete analysis for BOLD

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.50
Price